📰 Clinical Development News
Page 41 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
February 1, 2024
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiativesDURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer ...
January 31, 2024
GSK plc’s small molecule Omjjara (momelotinib), was granted marketing authorization (MA) yesterday (January 31) by the Medicines and Healthcare products Regulatory Agency (MHRA).
January 30, 2024
Bristol Myers Squibb reports that health authorities have agreed to review three regulatory applications for Breyanzi : two applications have been accepted by the US Food and Drug Administration , the...
January 30, 2024
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The
January 30, 2024
/PRNewswire/ -- EicOsis Human Health, a pharmaceutical company engaged in the development of a novel category of non-narcotic oral analgesics centered around...
January 30, 2024
Clinical programmers can now further accelerate clinical study reporting, submission analysis and statistical modeling and more thanks to a new product in EDETEK’s informatics platform, Conform.
January 30, 2024
With colorectal cancer (MRC) being the second biggest cancer type in Hong Kong, it is positive news that Hutchmed has received marketing approval for its Elunate (fruquintinib) small molecule treatment.
January 29, 2024
PRINCETON - Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization approval of Abecma for...
January 29, 2024
/PRNewswire/ -- Daewoong Pharmaceuticals Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis...
January 29, 2024
Clinical-stage precision oncology company, Repare Therapeutics Inc., has received a $40 million milestone payment from Roche after dosing the first patient in a clinical trial.